BREATH Genome Engineering of Macrophages to Mediate Regeneration of the Fibrotic Lung
- Coordinator
- Medizinische Hochschule Hannover, Germany
- Runs
- 1 October 2026 to 30 September 2030
- Status
- Running
- EU funding
- €10.0m
- Total cost
- €10.0m
- Partners
- 13 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101286746
What the project is doing
In the project's own words, from its summary on CORDIS.
Idiopathic Pulmonary Fibrosis (IPF), affects over 100,000 people in Europe and more than 3 million globally, causing scarring of lung tissue, respiratory decline and death. IPF remains a serious unmet medical need with limited treatment options. Genetic engineering of macrophages to create an innovative sense and respond-based cellular therapy offers a new solution. BREATH will develop functionally improved macrophages, genetically designed and enhanced to counteract dysfunctional macrophages in the fibrotic lung, restoring immune balance and halting fibrosis effectively.
BREATH will harness modern synthetic biology concepts and integrate state-of-the art knowledge in genetic switches to generate genetically modified human macrophages using known IPF gene targets and innovative strategies for tight control of therapeutic genes. Simultaneously, we will accelerate the discovery and implementation of new pro-regenerative synthetic gene circuits for the treatment of IPF through gene silencing.
The cell products will be evaluated for efficacy and safety using state of the art in vitro and ex vivo models of the human lung and in vivo, using pre-clinical mouse models of fibrosis. To facilitate the clinical translation of the products developed, we will carry out a feasibility pilot study in healthy volunteers, together with a programme of clinician, patient and regulatory engagement. Furthermore, we will develop a stratification framework and collect and integrate the information required to inform future clinical translation.
By positioning genetically enhanced macrophages as a new class of regenerative medicine, BREATH will, in the long term, reduce the societal and economic burden of IPF and pave the way for other innovative therapies for fibrotic diseases including the liver and heart.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Medizinische Hochschule Hannover | Hannover | Germany | Coordinator |
| European Pulmonary Fibrosis Federation | Overijse | Belgium | Participant |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Helmholtz-Zentrum Fur Infektionsforschung GmbH | Braunschweig | Germany | Participant |
| Universitaetsklinikum Freiburg | Freiburg | Germany | Participant |
| Royal College of Surgeons in Ireland | Dublin 2 | Ireland | Participant |
| Ospedale San Raffaele SRL | Milano | Italy | Participant |
| Seoul National University | Seoul | South Korea | Participant |
| Seoul National University Hospital | Seoul | South Korea | Participant |
| Instituto De Biologia Experimental E Tecnologica | Oeiras | Portugal | Participant |
| Ccrm Nordic AB | Molndal | Sweden | Participant |
| Laverock Therapeutics Ltd | Chandler's Ford | United Kingdom | Participant |
| Modus Research and Innovation Limited | Dundee | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI